Clinical trials: completed, sponsored by Merck Sharp & Dohme LLC
Fungal Infection
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)
The purpose of this study is to evaluate the pharmacokinetics and safety of posaconazole intravenous solution in Chinese participants at high risk for invasive fungal infections.
- Trial name
- NCT03336502
- Testing
- Posaconazole
- Where
- 7 sites in China
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia.
- Trial name
- NCT02336555
- Testing
- MK-8291
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
This is a 2-part study. The purpose of Part A is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg for 12 weeks in the treatment of chronic HCV GT1, GT4, or GT6…
- Trial name
- C-EDGE CO-STAR (NCT02105688)
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
- Volunteers
- 301 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infections
Observational Data Analysis in EuroSIDA (MK-0518-058)
The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients.
- Trial name
- NCT01078233
- Volunteers
- 6,617 people
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two periods.
- Trial name
- NCT02576054
- Testing
- V501
- Where
- Japan
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at reappearance of T2 (the amplitude of the first response of second twitch to…
- Trial name
- NCT00552617
- Testing
- Sugammadex, Rocuronium, Vecuronium
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
The objective of the trial was to show equivalence in recovery from neuromuscular block after a single dose of 4.0 mg/kg sugammadex, administered at first twitch (T1) 3-10% after continuous infusion of rocuronium, between…
- Trial name
- NCT00559468
- Testing
- Sugammadex, Rocuronium, Sevoflurane
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Adult
Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and the pharmacokinetic (PK) of single day…
- Trial name
- NCT01054300
- Testing
- Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of…
- Trial name
- NCT00769132
- Testing
- Comparator: niacin + laropiprant, Comparator: niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092430
- Testing
- V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)
The purpose of this study was to demonstrate in adult patients a faster recovery from a neuromuscular block with 2.0 mg/kg Org 25969 (sugammadex) after rocuronium as compared to 50 ug/kg neostigmine after cisatracurium when…
- Trial name
- NCT00451100
- Testing
- Sugammadex, neostigmine
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)
To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.
- Trial name
- NCT00482638
- Testing
- MK0493
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)
A two-part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin /metformin (50/500 and 50/1000 mg) Fixed-Dose Combination (FDC) tablet and co-administration of a single dose of…
- Trial name
- NCT00961857
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500 mg, Comparator: sitagliptin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced, Metastatic Solid Tumors
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
The purpose of this study is to compare the safety and tolerability of several dose levels of MK-2206 in combination with chemotherapy and targeted therapy agents in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT00848718
- Testing
- MK-2206, docetaxel, erlotinib
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic…
- Trial name
- NCT00696709
- Testing
- Comparator: V212
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)
The study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-4250 monotherapy in anti-retroviral therapy (ART)-naïve, HIV-1 infected participants.
- Trial name
- NCT03351699
- Testing
- MK-4250
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
This study is designed to evaluate the safety, tolerability, and immunogenicity of two different lots of V114 in healthy infants 6 to 12 weeks (>=42 days to <=90 days) of age.
- Trial name
- NCT02987972
- Testing
- V114 Lot 1, V114 Lot 2, Prevnar 13™
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.